3-(2-氰基-2,2-二苯基乙基)-8,8-二甲基-8-氮杂二环[3.2.1]辛烷溴化物 | 850607-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-氰基-2,2-二苯基乙基)-8,8-二甲基-8-氮杂二环[3.2.1]辛烷溴化物
• 中文别名: 达罗溴铵
• 英文名称: Darotropium bromide
• 英文别名: 3-[(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile;bromide
• CAS: 850607-58-8
• 化学式: C24H29BrN2
• 分子量: 425.4
• InChiKey: CWRNUVNMUYSOFQ-FUHGUCTDSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropionitrile 以83的产率得到3-(2-氰基-2,2-二苯基乙基)-8,8-二甲基-8-氮杂二环[3.2.1]辛烷溴化物
  参考文献：
  名称：

  Muscarinic acetycholine receptor antagonists

  摘要：

  提供了肌动蛋白乙酰胆碱受体拮抗剂及其使用方法。

  公开号：

  US20070105895A1

文献信息

• Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient
  申请人：Cooper Anne Elizabeth

  公开号：US20120028941A1

  公开（公告）日：2012-02-02

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase activator; an IKK2 kinase inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; a MABA compound; an MPO inhibitor; a muscarinic antagonist; a PDE4 inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

  该发明提供了一种制药产品、套装或组合物，包括第一活性成分N-环丙基-3-氟-4-甲基-5-[3-[[1-[2-[2-(甲氨基)乙氧基]苯基]环丙基]氨基]-2-氧代-1(2H)-吡嗪基]-苯甲酰胺或其盐，以及从以下选取的第二活性成分：非类固醇糖皮质激素受体（GR受体）激动剂；抗氧化剂；β2肾上腺素受体激动剂；CCR1拮抗剂；趋化因子拮抗剂（非CCR1）；皮质类固醇；CRTh2拮抗剂；DPI拮抗剂；组蛋白去乙酰化酶激活剂；IKK2激酶抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MABA化合物；MPO抑制剂；毛细血管抗药性剂；PDE4抑制剂；PPARγ激动剂；蛋白酶抑制剂；他汀类药物；前列腺素拮抗剂；扩血管剂；或者ENAC拮抗剂（上皮钠通道拮抗剂）；以及其在呼吸系统疾病治疗中的用途。
• Muscarinic acetycholine receptor antagonists
  申请人：Busch-Petersen Jakob

  公开号：US20070105895A1

  公开（公告）日：2007-05-10

  Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

  提供了肌动蛋白乙酰胆碱受体拮抗剂及其使用方法。
• PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT
  申请人：AstraZeneca AB

  公开号：US20150141387A1

  公开（公告）日：2015-05-21

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a β2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase activator; an IKK2 kinase inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; a MABA compound; an MPO inhibitor; a muscarinic antagonist; a PDE4 inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

  本发明提供一种药物产品、试剂盒或组合物，包括第一种活性成分 N-环丙基-3-氟-4-甲基-5-[3-[[1-[2-[2-(甲基氨基)乙氧]苯基]环丙基]氨基]-2-氧代-1(2H)-吡嗪基]-苯甲酰胺或其盐，以及从以下选择的第二种活性成分：非类固醇糖皮质激素受体（GR受体）激动剂；抗氧化剂；β2肾上腺素受体激动剂；CCR1拮抗剂；趋化因子拮抗剂（不包括CCR1）；类固醇激素；CRTh2拮抗剂；DPI拮抗剂；组蛋白去乙酰化酶激活剂；IKK2激酶抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MABA化合物；MPO抑制剂；毒蕈碱受体拮抗剂；PDE4抑制剂；PPARγ激动剂；蛋白酶抑制剂；他汀类药物；血栓素拮抗剂；扩血管剂；或Epithelial Sodium-channel拮抗剂（ENAC拮抗剂）；以及其在呼吸系统疾病治疗中的用途。
• Inhalation compositions comprising muscarinic receptor antagonist
  申请人：Arven Ilac Sanayi Ve Ticaret A.S.

  公开号：US10105316B2

  公开（公告）日：2018-10-23

  The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

  本发明涉及通过吸入器给药的药粉组合物。更具体地说，它涉及的药用粉末组合物在吸入器装置中使用时，具有含量均匀性和所需的稳定性。
• NOVEL COMBINATIONS
  申请人：Burkamp Frank

  公开号：US20100261690A1

  公开（公告）日：2010-10-14

  The invention provides a pharmaceutical product comprising, in combination, (1) a named glucocorticosteroid receptor agonist and (2) a β 2 adrenoreceptor agonist, a dual β 2 adrenoreceptor agonist/M 3 receptor antagonist, a muscarinic antagonist, a p38 kinase inhibitor, a neutrophil elastase inhibitor, a phosphodiesterase PDE4 inhibitor, an IKK2 kinase inhibitor or a non-steroidal glucocorticoid receptor agonist, and the use of said product in treating respiratory diseases.